By Fineline Cube 
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that it has received clinical trial approval from the US Food and Drug Administration (FDA) for its investigational drug HSK47388. This oral, highly selective drug is being developed for the treatment of autoimmune diseases.
Preclinical Findings
Preclinical studies have demonstrated that HSK47388 can dose-dependently inhibit inflammatory responses in rats. The drug has also shown favorable tolerability and a wide safety margin, highlighting its potential as a promising therapeutic option.
Clinical Review in China
In addition to the FDA approval, HSK47388 is currently under clinical review in China. This parallel development strategy underscores Haisco’s commitment to advancing novel therapies for autoimmune diseases on a global scale.-Fineline Info & Tech